Partillion Bioscience Corporation (“Partillion”) announced a new study led by UCLA Professor Dino Di Carlo that showcases the therapeutic potential of extracellular vesicles (EVs). Utilizing Partillion’s Nanovial technology, which allows screening of thousands of individual cells, the study identified high EV-secreting stem cells and used them in mice, resulting in improved tissue regeneration after cardiac injury. These findings underscore the importance of EV secretion in regenerative therapies and suggest that selecting cells based on EV secretion could boost therapeutic effectiveness. EVs, which are lipid membrane-encapsulated particles, play key roles in cell communication and disease progression. They recruit regenerative and anti-inflammatory cells, but the variability in EV secretion among stem cells complicates therapeutic development. Traditional methods, which analyze EV-secreting cells in bulk, often overlook this variability and destroy the cells, hindering optimization of EV-based treatments.